Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

@article{Griffin2003DiscoveryOA,
  title={Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome},
  author={John H. Griffin and Joey Leung and Rebecca J Bruner and Michael A. Caligiuri and Roger Briesewitz},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2003},
  volume={100},
  pages={7830 - 7835}
}
Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disease of unknown etiology. Recently, it has been reported that imatinib mesylate (Gleevec), an inhibitor of Bcr-Abl kinase useful in the treatment of chronic myeloid leukemia, is also effective in treating HES; however, the molecular target of imatinib in HES is unknown. This report identifies a genetic rearrangement in the eosinophilic cell line EOL-1 that results in the expression of a fusion protein comprising an N… 

Figures from this paper

The FIP 1 L 1-PDGFR fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis , classification , and management
TLDR
The identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptorgene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1).
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
TLDR
The identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1).
Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
TLDR
The efficacy of relatively low imatinib concentrations in HES, mediated by inhibition of Fip1L1-PDGFRalpha kinase activity, causally implicates FIP1L 1-PDGFRA in the pathogenesis in certain HES patients.
The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
TLDR
The identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1).
The FIP1L1-PDGFR&agr; kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia
TLDR
The discovery of the FIP1L1-PDGFRA fusion gene in the hypereosinophilic syndrome is an example of the power of clinical translational research and identifies interstitial chromosomal deletion as a novel mechanism to generate oncogenic tyrosine kinase fusion genes.
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia
TLDR
The utility of screening forPDGFRA kinase domain overexpression in patients with IHES is demonstrated and a third PDGFRA fusion partner in chronic myeloproliferative disorders is identified.
Imatinib for the treatment of hypereosinophilic syndromes
  • G. Helbig
  • Medicine
    Expert review of clinical immunology
  • 2018
TLDR
Imatinib mesylate, a first generation tyrosine kinase inhibitor, has revolutionized the therapeutic approach to patients with hypereosinophilic syndromes and detectable F/P fusion gene.
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics
TLDR
Molecular characterization of HES in 35 patients with normal karyotype by conventional cytogenetic analysis revealed scattered breakpoints in FIP1L1-exons (10–13), whereas breakpoints were restricted to exon 12 of PDGFRA.
Molecular Classification and Pathogenesis of Eosinophilic Disorders: 2005 Update
  • J. Gotlib
  • Medicine, Biology
    Acta Haematologica
  • 2005
TLDR
Success in establishing the molecular basis of a group of once seemingly heterogeneous diseases has now the laid the foundation for establishing a semi-molecular classification scheme of eosinophilic disorders.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
TLDR
The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
TLDR
Although the drug was well tolerated in most patients, a previously unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding patient with HES within the first week of treatment.
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
TLDR
Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB and all responses were durable at 9 to 12 months of follow-up.
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
TLDR
It is concluded that t(5;10)(q33;q21.2) is a novel translocation in BCR-ABL-negative chronic myeloid leukemia and that this abnormality results in an H4-PDGFbetaR fusion gene, which strengthens the association between myeloproliferative disorders and deregulated tyrosine kinases.
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
TLDR
Using 5' rapid amplification of complementary DNA ends-polymerase chain reaction (RACE-PCR) on patient RNA, rabaptin-5 was identified as a novel partner fused in-frame to the PDGFbetaR gene, and a new fusion protein links together 2 important pathways of growth regulation.
Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.
TLDR
The expression of a CEV14-PDGFRbeta fusion gene in association with aggressive leukemia progression suggests that this protein has oncogenic potential.
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.
TLDR
The identification and cloning of a rare variant translocation, t(4;22)(q12;q11), in two patients with a CML-like myeloproliferative disease (MPD), and the first report of a fusion gene that involves PDGFRA is reported.
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
TLDR
Mutational analysis showed that the amino-terminal H4 leucine zipper domain, as well as H4 amino acids 101 to 386, was required for efficient induction of factor-independent growth of Ba/F3 cells.
...
1
2
3
...